Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups
Latest Information Update: 25 Aug 2022
At a glance
- Drugs Revacept (Primary)
- Indications Carotid stenosis; Embolism and thrombosis; Stroke; Transient ischaemic attacks
- Focus Proof of concept; Therapeutic Use
- Sponsors advanceCor
- 25 Aug 2022 According to an AdvanceCOR media release, Professor Klaus Groschel is the principal investigator for this study.
- 25 Aug 2022 Results published in the advanceCor Media Release.
- 13 Jun 2022 Primary endpoint has not been met. (stroke or death, transient ischemic attack, myocardial infarction, coronary intervention, and bleeding complications during follow-up- 40 mg Revacept), as per Results published in the Stroke, as per Results published in the Stroke